Press "Enter" to skip to content

Darolutamide Gets Priority Review for Non-Metastatic Castration-Resistant Prostate Cancer – Cancer Therapy Advisor

admin 0

Darolutamide Gets Priority Review for Non-Metastatic Castration-Resistant Prostate Cancer  Cancer Therapy Advisor

The FDA has accepted for Priority Review the New Drug Application for darolutamide (Bayer and Orion), an investigational treatment for non-metastatic …

“prostate cancer” – Google News

(Visited 2 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *